Linezolid Delivery Methods to the Site of Tuberculosis Inflammation: a Systematic Review
- 14 May 2026
- journal article
- review article
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (2)
Abstract
50 scientific publications between 2018 and 2025 were analyzed, focusing on drug delivery systems and benefits of linezolid-loaded nanoparticles. Orally administered anti-tuberculosis drugs do not always achieve sufficient bactericidal concentrations at the site of infection, regardless of their serum levels. Consequently, even with treatment adherence, approximately 1% of patients may develop multidrug-resistant tuberculosis (MDR-TB) due to pharmacokinetic variability. This highlights the need for advanced delivery systems that ensure targeted drug release directly into the affected lung tissue. Nanoformulations of linezolid (e.g., dry powders, aerosols) have been developed. These formulations remain stable for up to 6 months and increase bioavailability to 55.2%, enabling dose reduction. This opens up real prospects for lowering the therapeutic dose of the drug.Keywords
This publication has 45 references indexed in Scilit:
- Clinically Relevant Metallic Nanoparticles in Tuberculosis Diagnosis and TherapyAdvanced Therapeutics, 2024
- Evolution of drug delivery systems: From 1950 to 2020 and beyondJournal of Controlled Release, 2021
- Pulmonary Delivery of Linezolid Nanoparticles for Treatment of Tuberculosis: Design, Development, and OptimizationJournal of Pharmaceutical Innovation, 2020
- Nanoparticle-mediated macrophage targeting—a new inhalation therapy tackling tuberculosisDrug Delivery and Translational Research, 2020
- Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic interventionDrug Delivery and Translational Research, 2020
- Reaching consensus on drug resistance conferring mutationsInternational Journal of Mycobacteriology, 2016
- Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoringEuropean Journal of Clinical Pharmacology, 2016
- Effect of particle size on biological response by human monocyte-derived macrophagesBiosurface and Biotribology, 2016
- Pulmonary drug delivery systems for tuberculosis treatmentInternational Journal of Pharmaceutics, 2015
- Morphological aspects of particle uptake by lung phagocytesMicroscopy Research and Technique, 2002